4-<3-<(methoxy)methoxy>phenyl>acetic acid | 160721-41-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-<3-<(methoxy)methoxy>phenyl>acetic acid
• 英文别名: 3-methoxymethoxyphenylacetic acid；2-[3-(methoxymethoxy)phenyl]acetic acid
• CAS: 160721-41-5
• 化学式: C₁₀H₁₂O₄
• 分子量: 196.203
• InChiKey: WLZPAZAHLVZODH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-<3-<(methoxy)methoxy>phenyl>acetic acid 在 ethandithiol 、 BF₅O 、 camphor-10-sulfonic acid 、 碘 、 二异丁基氢化铝 、 对甲苯磺酸 、 magnesium 、 N,N'-羰基二咪唑 作用下， 以 二氯甲烷 、 乙腈 、 苯 为溶剂， 反应 29.83h， 生成 3,3-ethylenedioxy-1,8-dihydroxy-1,2,3,4-tetrahydronaphthalene
  参考文献：
  名称：

  Regioselective synthesis of 1,8-dihydroxytetralins through a tandem reduction/intramolecular hydroxyalkylation of 4-(3-hydroxyphenyl)alkanoates

  摘要：

  A series of 4-(3-hydroxyphenyl)butanoates 3 has been prepared and transformed into 1,8-dihydroxytetralins of general formula 2 by treatment with 2 equivalents of DIBALH followed by quenching with aqueous NH4Cl. A possible mechanism for this novel totally regioselective intramolecular hydroxyalkylation is suggested and the factors affecting the stability of 1,8-dihydroxytetralins 2 are also discussed.

  DOI：

  10.1016/s0040-4020(01)89307-8
• 作为产物：
  描述：

  3-羟基苯乙酸 在 氢氧化钾 、 三乙胺 作用下， 以 甲醇 、 水 、 乙腈 为溶剂， 反应 6.0h， 生成 4-<3-<(methoxy)methoxy>phenyl>acetic acid
  参考文献：
  名称：

  Regioselective synthesis of 1,8-dihydroxytetralins through a tandem reduction/intramolecular hydroxyalkylation of 4-(3-hydroxyphenyl)alkanoates

  摘要：

  A series of 4-(3-hydroxyphenyl)butanoates 3 has been prepared and transformed into 1,8-dihydroxytetralins of general formula 2 by treatment with 2 equivalents of DIBALH followed by quenching with aqueous NH4Cl. A possible mechanism for this novel totally regioselective intramolecular hydroxyalkylation is suggested and the factors affecting the stability of 1,8-dihydroxytetralins 2 are also discussed.

  DOI：

  10.1016/s0040-4020(01)89307-8

文献信息

• Imino ether derivative compounds and drugs containing the compounds as the active ingredient
  申请人：Ishida Akiharu

  公开号：US20070167490A1

  公开（公告）日：2007-07-19

  The compound represented by formula (I) (wherein R 1 and R 2 are cyclic group which may have a substituent(s) and so on; W is a spacer of which main chain has an atom number of 1-6.; X is —O— and so on; ring A is cyclic group which may have a substituent(s); Y is a spacer of which main chain has an atom number of 1-6 and so on; Z is acidic group.) a salt thereof, a solvent thereof or an N-oxide thereof, or a prodrug thereof Since the compounds in the present invention have a regulatory activity for peroxisome proliferator activated receptor, the compounds in the present invention are useful as a preventive and/or therapeutic agent for diseases associating metabolic disorders (e.g., hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipidemia, atherosclerosis, hypertension, circulatory diseases, overeating, ischemic heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or a VLDL cholesterol-lowering agent and a drug for relief from risk factors of diabetes or metabolic syndrom.

  化合物的化学式为（I）（其中R1和R2是环状基团，可以具有取代基等；W是具有1-6个原子数的主链的间隔物；X是-O-等；环A是环状基团，可以具有取代基等；Y是具有1-6个原子数的主链的间隔物等；Z是酸性基团）其盐、溶剂或N-氧化物，或其前药。由于本发明中的化合物具有对过氧化物酶体增殖物激活受体的调节活性，因此本发明中的化合物可用作预防和/或治疗代谢紊乱（如高胆固醇血症、高脂蛋白血症等）、高脂血症、动脉硬化、高血压、循环系统疾病、暴饮暴食、缺血性心脏病等的药物，以及一种升高HDL胆固醇的药物，降低LDL胆固醇和/或VLDL胆固醇的药物，以及缓解糖尿病或代谢综合征风险因素的药物。
• FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1535915A1

  公开（公告）日：2005-06-01

  The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R1 is a hydrogen atom or an optionally substituted hydrocarbon group, R2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X1 is an oxygen atom or a sulfur atom, X2 is a bond, an oxygen atom or -S(O)n- (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, -S(O)m-, -C(=O)-N(R3)- or -N(R3)-C(=O)- (R3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M1, M2 and M3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M4 is an optionally substituted divalent aliphatic hydrocarbon group] or a salt thereof, which is useful as a prophylactic and/or therapeutic agent for lipid metabolism abnormality, arteriosclerotic disease and sequelae thereof, diabetes mellitus and the like.

  本发明提供了一种由式（I）表示的化合物： [其中 R 为任选取代的烃基或任选取代的杂环基，p 为 0、1 或 2，当 p 为 2 时，每个 R 可以相同或不同，R1 为氢原子或任选取代的烃基，R2 为任选取代的芳香基、环 A 是任选取代的单环芳香环或任选取代的双环芳香融合环，X1 是氧原子或硫原子，X2 是键、氧原子或 -S(O)n- （其中 n 是 0、1 或 2），Y 是键、氧原子、-S(O)m-、-R3是氢原子、任选取代的烃基或任选取代的杂环基，m是0、1或2），M1、M2和M3可以相同或不同，各自独立地是键或任选取代的二价脂族烃基、和 M4 是任选取代的二价脂族烃基]或其盐，可用作脂质代谢异常、动脉硬化疾病及其后遗症、糖尿病等的预防和/或治疗剂。
• IMINO ETHER DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1602642A1

  公开（公告）日：2005-12-07

  The compound represented by formula (I) (wherein R1 and R2 are cyclic group which may have a substituent(s) and so on.; W is a spacer of which main chain has an atom number of 1-6.; X is -O- and so on.; ringA is cyclic group which may have a substituent(s).; Y is a spacer of which main chain has an atom number of 1-6 and so on.; Z is acidic group.) a salt thereof, a solvent thereof or an N-oxide thereof or a prodrug thereof Since the compounds in the present invention have a regulatory activity for peroxisome proliferator activated receptor, the compounds in the present invention are useful as a preventive and/or therapeutic agent for diseases associating metabolic disorders (e.g., hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipidemia, atherosclerosis, hypertension, circulatory diseases, overeating, ischemic heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or a VLDL cholesterol-lowering agent and a drug for relief from risk factors of diabetes or metabolic syndrom.

  式(I)代表的化合物 (其中 R1 和 R2 为环状基团，可带有取代基等；W 为间隔基，其主链的原子序数为 1-6；X 为-O-等；ringA 为环状基团，可带有取代基等；Y 为间隔基，其主链的原子序数为 1-6；Z 为酸性基团)。)的盐、其溶剂或其 N-氧化物或其原药 由于本发明中的化合物具有过氧化物酶体增殖物活化受体的调节活性，因此本发明中的化合物可用作与代谢紊乱有关的疾病（如高胆固醇血症、高血脂症、高血压、高血糖、高血脂症等）的预防和/或治疗剂、高胆固醇血症、高脂蛋白血症等）、高血脂症、动脉粥样硬化、高血压、循环系统疾病、暴饮暴食、缺血性心脏病等相关疾病的预防和/或治疗剂、高密度脂蛋白胆固醇升高剂、低密度脂蛋白胆固醇和/或低密度脂蛋白胆固醇降低剂以及缓解糖尿病或代谢综合征危险因素的药物。
• Furan or thiopene derivative and medicinal use thereof
  申请人：Hamamura Kazumasa

  公开号：US20060100261A1

  公开（公告）日：2006-05-11

  The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R 1 is a hydrogen atom or an optionally substituted hydrocarbon group, R 2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X 1 is an oxygen atom or a sulfur atom, X 2 is a bond, an oxygen atom or —S(O) n — (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, —S(O) m —, —C(═O)—N(R 3 )— or —N(R 3 )—C(═O)— (R 3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M 1 , M 2 and M 3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M 4 is an optionally substituted divalent aliphatic hydrocarbon group] or a salt thereof, which is useful as a prophylactic and/or therapeutic agent for lipid metabolism abnormality, arteriosclerotic disease and sequelae thereof, diabetes mellitus and the like.

  本发明提供了一种由式（I）表示的化合物： [其中 R 为任选取代的烃基或任选取代的杂环基，p 为 0、1 或 2，当 p 为 2 时，每个 R 可以相同或不同，R 1 是氢原子或任选取代的烃基，R 2 是任选取代的芳香基团，环 A 是任选取代的单环芳香环或任选取代的双环芳香融合环，X 1 是氧原子或硫原子，X 2 是键、氧原子或 -S(O) n - 其中 n 为 0、1 或 2），Y 为键、氧原子、-S(O) m -、-C(═O)-N(R 3 )-或-N(R 3 )-C(═O)-(R 3 是氢原子、任选取代的烃基或任选取代的杂环基，且 m 是 0、1 或 2），M 1 , M 2 和 M 3 可以相同或不同，且各自独立地为键或任选取代的二价脂族烃基，以及 M 4 是任选取代的二价脂族烃基]或其盐，可用作脂质代谢异常、动脉硬化疾病及其后遗症、糖尿病等的预防和/或治疗剂。
• EP1535915
  申请人：——

  公开号：——

  公开（公告）日：——